Traditional prenatal screening can pose challenges for healthcare providers and their patients. With up to 30% false negative rates and 5% false positive rates, current screening can lead hundreds of thousands of women to undergo unnecessary invasive procedures and risk fetal loss. However, with the advent of DNA sequencing and other technological advancements over the last three decades, one of the greatest leaps forward in molecular diagnostics has been the introduction of "NIPT" or non-invasive prenatal testing. NIPT offers pregnant patients as early as 10 weeks' gestation an accurate and personalized method of detecting fetal trisomies linked to Down syndrome and others conditions. To learn more about how the Harmony Prenatal Test can revolutionize your practice for fetal trisomy detection, you are invited to read the October issue of Contemporary Ob-Gyn. The Harmony blood test is capable of reliably identifying and counting cell-free DNA fragments in maternal blood, determining whether a fetal trisomy may be present. Ariosa, Harmony, and Harmony Prenatal Test are trademarks of Ariosa Diagnostics, Inc.

 
You are subscribed to %%list.name%% as %%emailaddr%%. Click here to unsubscribe or edit your member profile.

To ensure delivery to your inbox, please add us to your address book. If you need help doing this, click here.

Advanstar Communications provides certain customer contact data (such as customers' names, addresses, phone
numbers and e-mail addresses) to third parties who wish to promote relevant products, services and other
opportunities which may be of interest to you. If you do not want Advanstar Communications to make your contact
information available to third parties for marketing purposes, simply call (toll free) 866-529-2922 at any time, or
fax us at 218-740-6417. Outside the U.S., please phone 218-740-6395. Contact us by mail at Advanstar
Communications Inc., 131 West First St., Duluth, MN 55802-2065, USA.